To determine the feasibility and toxicity of using prostate-specific membrane antigen-positron emission tomography (PSMA-PET) and multi-parametric magnetic resonance imagining (mpMRI) to guide target volumes for patients with unfavorable-risk prostate cancer receiving radiation.
COM_RESEARCHSTUDIES_DETAIL_HEADER_BASIC_CONTACT_4
North Carolina (Statewide)
Michael Repka
Radiation Oncology - Chapel Hill
Clinical or Medical
Interventional
Cancer (Prostate)
19-0843
Copyright © 2013-2022 The NC TraCS Institute, the integrated home of the NIH Clinical and Translational Science Awards (CTSA) Program at UNC-CH. This website is made possible by CTSA Grant UL1TR002489 and the National Center for Advancing Translational Sciences.
Questions?
